Results 31 to 40 of about 35,617 (253)
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Biomolecules, 2022 Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is)
Francesca Romana Prandi +8 more
doaj +1 more source
Российский кардиологический журнал, 2021 The development of chronic kidney disease (CKD) is a risk factor not only for cardiovascular diseases, but also for heart failure (HF). This article is a literary review on the use of Sodium-glucose co-transporter-2 (NGLT2) inhibitors in patients with ...
M. M. Batyushin
doaj +1 more source
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
Drugs in Context, 2014 Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj +1 more source
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study
JRSM Open, 2016 Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
Amira Obeid +3 more
doaj +1 more source
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential [PDF]
Cardiovascular Drugs and Therapy, 2020 AbstractSodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and cardiovascular mortality.
Brito, Dulce +9 more
openaire +3 more sources
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
Российский кардиологический журнал, 2021 The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes.
E. V. Kovalenko +3 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus.
Chen Li +7 more
doaj +1 more source
Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
European Heart Journal Supplements, 2022 Abstract The 2021 guidelines of the European Society of Cardiology on the diagnosis and therapy of heart failure (HF) introduced relevant changes in the pharmacological treatment of chronic HF. Among these, certainly the most significant was the introduction in the therapeutic flow-chart (with the highest recommendation level) of the ...
Cice, Gennaro +2 more
openaire +2 more sources
Discerning protein pools by selective staining with self‐labeling tags
FEBS Letters, EarlyView.Cell surface proteins have an intra‐ and extracellular pool. Combining genetic fusion to self‐labeling tags that can be addressed with small molecule fluorophores allows separating these pools. We highlight recent developments and techniques for state‐of‐the‐art interrogation of cell surface proteins in the complex tissue setting.
Kati Fischermanns, Johannes Broichhagen
wiley +1 more source
Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
Journal of Education, Health and Sport, 2022 Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski +3 more
doaj +1 more source